Global Thrombocytopenia Clinical Trials Market Sees Significant Growth in 2025
• The global thrombocytopenia clinical trials landscape is expanding rapidly with over 25 pharmaceutical companies developing 25+ treatment therapies, according to recent market analysis.
• Key industry players including GSK, Novartis, Amgen, and Sanofi are leading clinical development efforts, with several promising candidates in late-stage trials showing efficacy in reducing thrombocytopenia events.
• Recent advances include Takeda's TAK-755 demonstrating 60% reduction in thrombocytopenia events compared to standard of care, and HUTCHMED completing enrollment for its pivotal Phase III ESLIM-01 trial of sovleplenib for immune thrombocytopenia.
PG2® Plus Chemoradiotherapy Improves Survival in Esophageal Cancer Patients
• A clinical study by PhytoHealth Corporation shows that Astragalus Polysaccharides (PG2®) combined with chemoradiotherapy (CCRT) significantly improves survival in advanced esophageal cancer patients.
• Patients receiving PG2® with CCRT had longer overall survival and a higher tumor objective response rate compared to those receiving CCRT alone, indicating enhanced treatment efficacy.
• PG2® modulates the tumor immune microenvironment (TIME), strengthens the immune system, and suppresses tumor growth, offering a new approach to esophageal cancer treatment.
• The study suggests PG2® can help patients complete cancer treatment by reducing inflammation, improving strength, and mitigating cancer-related fatigue, leading to better therapeutic outcomes.
© Copyright 2025. All Rights Reserved by MedPath